Onsdag 28 Oktober | 18:57:06 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Respiratorius - Undramatic quarter

2024-08-06 11:09:00

Redeye provides a research update following the Q2 2024 report from Respiratorius. We postpone the estimated timing of a licensing deal to 2025e and provide an overview of the sentiment in the biopharma deal landscape. We also make minor other changes related to the valuation, resulting in a reduced fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/